BSR_18_0092_S48
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.420
- ANDROGEN_RESPONSE+0.280
- BILE_ACID_METABOLISM+0.250
- ESTROGEN_RESPONSE_EARLY+0.240
- HEDGEHOG_SIGNALING+0.210
- ANGIOGENESIS+0.180
- WNT_BETA_CATENIN_SIGNALING+0.170
- HYPOXIA+0.160
- PEROXISOME+0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.450
- E2F_TARGETS-0.380
- G2M_CHECKPOINT-0.340
- ALLOGRAFT_REJECTION-0.320
- INFLAMMATORY_RESPONSE-0.300
- PI3K_AKT_MTOR_SIGNALING-0.290
- MTORC1_SIGNALING-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- MYC_TARGETS_V2-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_08_0188_C3_S52 | — | A | 0.859 |
| 2 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.849 |
| 3 | 20030017.LumA | — | B | 0.843 |
| 4 | TCGA-AN-A0FS-01A-11R-A034-07 | — | A | 0.823 |
| 5 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.819 |
| 6 | TCGA-S3-AA14-01A-11R-A41B-07 | — | A | 0.815 |
| 7 | 20020009.LumA | — | A | 0.813 |
| 8 | TCGA-E2-A15E-01A-11R-A12D-07 | — | A | 0.800 |
| 9 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.799 |
| 10 | TCGA-AC-A2FG-01A-11R-A17B-07 | — | A | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |